NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Well, I think NWBO's failure to educate and hold press conferences probably causes your sentiment. Nobody likes to be told about "luxury" in the same sentence as expanding the trial. Nobody likes to be told "actively considering it" and "a little bit" unless we are told clearly, what this might look like, that they do not have pfs knowledge -- even though they said this earlier and it is part and parcel of phase 3 trials.

Investors want to know why Linda could make predictions about DMC recommendation timelines 6 months ago, but now she apparently can't.

I want to know if Sitiain is correct -- that Germany will be able to enroll due to reimbursement requirements.

Nonetheless, this is good news.

1. It means Germany is manufacturing DCVAX-L for Germany and Europe (in addition to Great Britain), treating patients with DCVAX-L and paying for DCVAX-L.

2. It means the price negotiations are very near completion, because they need to pay reimbursement fees for patients starting therapy.

3. It means that the rest of Europe will then be able to calculate their reimbursement levels, using Germany's price as a keystone.

4. It means NWBO is a trailblazer that now is an expert in moving into a foreign market that has a high barrier to entry.

5. It means revenue.

6. It means the intrinsic value of this company is moving higher each day, not just due to ongoing direct information and possible L results, it has more value because of its incredible infrastructure and
ramping capabilities.